Navigation Links
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
Date:2/13/2008

lucosidase alfa),

which has been constrained by limited product supply, as the FDA has

yet to approve the larger scale manufacturing process for this product.

This supply constraint will have an estimated impact of $0.03 per

diluted share during the first quarter.

Product Sales

-- Sales of Myozyme are expected to increase to $320-$330 million this

year, compared with $201 million last year. The launch of this product

has been the most rapid for any of Genzyme's lysosomal storage disorder

treatments. In December, Genzyme announced that its post-marketing

Late-Onset Treatment Study of Myozyme met its co-primary endpoints,

confirming the benefit of the product for patients across the spectrum

of Pompe disease. The company has begun submitting the results of this

study for presentation at medical meetings and will pursue the

inclusion of the trial results in the product's labeling.

-- Sales of Fabrazyme(R) (agalsidase beta) are expected to reach $495-$505

million this year, compared with $424 million in 2007. The European

Commission has granted full marketing authorization for Fabrazyme,

making the product the only Fabry disease treatment to earn this

designation in Europe.

-- Sales of Cerezyme(R) (imiglucerase for injection) are expected to reach

$1.22-$1.24 billion this year, compared with $1.13 billion in 2007.

-- Sales of sevelamer therapies Renagel(R) (sevelamer hydrochloride) and

Renvela(R) (sevelamer carbonate) are expected to rise to $690-$700

million this year, compared with $603 million in 2007. Renvela was

approved by the FDA in October for the treatment of hemodialysis

patients, and Genzyme plans to launch the product on March 1. Genzyme

is currently engaged in active discussions with the FDA to expand the

product'
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
2. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
3. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Delaware Court Approves Bioenvision, Genzyme Joint Petition
6. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
7. Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities
8. March of Dimes Delivers a New Look
9. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
11. Gleevec, the targeted cancer pill, delivers more good news to patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... If there is one thing that drives ... head lice outbreak at their child’s school. While head lice ... is nothing short of a nightmare for many parents as ... children, or within their child’s classroom. Just when they think ... scratching again. , Local lice removal company, Lice Troopers ...
(Date:2/27/2015)... Philanthropy is a continuous force restoring people’s ... help to restore that faith by helping the people in ... husband/wife Realtor team gives to the local children in need ... while others have been added as the need arose. , ... haven and counseling for women who have suffered physical and ...
(Date:2/27/2015)... NewYork (PRWEB) February 27, 2015 The ... and trends in the global celiac disease market. It ... outlook, research and development activities, and investments. , Celiac ... of gluten damages the small intestine. Celiac disease often ... in every 100 people is affected by celiac disease ...
(Date:2/27/2015)... WI (PRWEB) February 27, 2015 UAS ... Adult Cubes, at Natural Products Expo West, March 6 ... are very excited to release the hands down best ... cream taste with an extra zing of Vitamin C. ... Cubes, winner of the NutrAward 2014, Delicious Living’s Supplement ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 The Willliams ... Plant in Lincoln County, Wyoming. The plant processes ... preparation for interstate natural gas pipeline transport. It also ... The Opal plant initially began operations in 1958, and ... growing natural gas production in Wyoming. The plant ...
Breaking Medicine News(10 mins):Health News:Anxiety over head lice among Miami parents as surge in head lice cases reported by local lice removal company Lice Troopers 2Health News:Mr. And Mrs. Smits Proves That Altruism Works All Year Round 2Health News:Global Celiac Disease Market Counts on Drug Launch for Growth 2Health News:Global Celiac Disease Market Counts on Drug Launch for Growth 3Health News:UAS LifeSciences to Launch UP4 Adult Cubes at Expo West 2Health News:Clean Water Systems Supplies Advanced Chlorine Disinfection Skid for Wyoming Gas Plant 2
... sickening erotica fantasies, two US teenagers in the Florida state ... woman, forcing her 12-year-old son to join the outrage , ... ,Authorities allege Avion Lawson, 14, and Nathan Walker, ... who forced their way into the woman's apartment in a ...
... of The Women's and Children's Hospital, Adelaide in Australia has ... the staff there are exposed to every day. ... of problems with ageing facilities in two of the hospital's ... risk". ,It states: "WCH is experiencing immediate facilities, ...
... Nora Ali, daughter of Bangladeshi immigrants to the United States, ... 17, won the final competition, held in Alabama Saturday, by ... said Wednesday, quoting website wcco.com. ,"I just want ... company with my elder sister who does stem cell research. ...
... developing the world's first vaccine against dengue fever as Singapore ... Friday. ,Clinical tests on up to 3,000 people ... Stephenne, GlaxoSmithKline Biologicals president. ,"We've been working on ... more or less," The Straits Times quoted Stephenne as saying. ...
... researchers say that a single drug for keeping both ... diabetes under check may soon be available. ... Medicine and Pharmacology at Tulane University School of Medicine, ... Sulfonylurea-based therapy has been found to significantly reduce glucose ...
... 36 percent since last year, local press reported Sunday, as ... ,The outbreak has killed 17 people in Thailand ... year, the English-language Nation newspaper reported, quoting figures from the ... by the virus, which is especially dangerous in children and ...
Cached Medicine News:Health News:US Teens Charged With Gang Raping a Woman 2Health News:US Teens Charged With Gang Raping a Woman 3Health News:Concerns Raised Over Risks for Patients and Staff in Australian Hospital 2
(Date:2/26/2015)... MOUNTAIN VIEW, Calif. , Feb. 26, 2015  IRIDEX ... will release its fourth quarter and full year 2014 financial ... 2015.   In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, March 5, ... other business developments. Interested parties may access the ...
(Date:2/26/2015)... 2015 Legislation passed today by the House ... help prevent inappropriate prescriptions in Medicare Part D from ... of Medicare Act (PIMA) of 2014 , introduced by ... (R-TX) and Ranking Member Jim McDermott (D-WA), recognizes ... and implement the right policies, said the Pharmaceutical Care ...
(Date:2/26/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/2vn6hh/radiation_therapy ) has ... - Global Strategic Business Report" report to their ... markets for Radiation Therapy Equipment in US$ Million by ... and Radiation Therapy Simulator. The report provides separate comprehensive ... Japan , Europe ...
Breaking Medicine Technology:IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2Radiation Therapy Equipment - Global Strategic Business Report 2015-2020: Linear Accelerator, Treatment Planning Systems, and Radiation Therapy Simulator 2
... Neurobiological Technologies, Inc. (Nasdaq: NTII ) ("NTI") announced ... dividend of $0.18 per share of common stock, which will ... as of November 30, 2009. The December 9, 2009 extraordinary ... to a plan of complete liquidation and dissolution and an ...
... , , WAYNE, Pa., Nov. 20 ... its fiscal first quarter ended September 30, 2009. ... decreased approximately $234,000, or 2.7%, to $8,435,000 during the three-month ... period last fiscal year. The Company reported the decreased ...
Cached Medicine Technology:Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share 2Escalon(R) Reports First Quarter Fiscal 2010 Results 2Escalon(R) Reports First Quarter Fiscal 2010 Results 3Escalon(R) Reports First Quarter Fiscal 2010 Results 4Escalon(R) Reports First Quarter Fiscal 2010 Results 5Escalon(R) Reports First Quarter Fiscal 2010 Results 6Escalon(R) Reports First Quarter Fiscal 2010 Results 7